US20020009789A1 - Powder containing physiologically active peptide - Google Patents
Powder containing physiologically active peptide Download PDFInfo
- Publication number
- US20020009789A1 US20020009789A1 US09/810,483 US81048301A US2002009789A1 US 20020009789 A1 US20020009789 A1 US 20020009789A1 US 81048301 A US81048301 A US 81048301A US 2002009789 A1 US2002009789 A1 US 2002009789A1
- Authority
- US
- United States
- Prior art keywords
- physiologically active
- active peptide
- weight
- powder
- nonionic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 180
- 239000000843 powder Substances 0.000 title claims abstract description 120
- 238000000034 method Methods 0.000 claims abstract description 93
- 239000007788 liquid Substances 0.000 claims abstract description 43
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 43
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 42
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 36
- 235000010355 mannitol Nutrition 0.000 claims abstract description 34
- 239000011230 binding agent Substances 0.000 claims abstract description 33
- 238000001035 drying Methods 0.000 claims abstract description 33
- 229930195725 Mannitol Natural products 0.000 claims abstract description 26
- 239000000594 mannitol Substances 0.000 claims abstract description 26
- 230000008569 process Effects 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 239000007864 aqueous solution Substances 0.000 claims description 37
- 238000002360 preparation method Methods 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 32
- 238000001694 spray drying Methods 0.000 claims description 30
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 26
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 26
- 239000000854 Human Growth Hormone Substances 0.000 claims description 26
- 230000006641 stabilisation Effects 0.000 claims description 24
- 238000011105 stabilization Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 20
- 239000000122 growth hormone Substances 0.000 claims description 18
- 238000004108 freeze drying Methods 0.000 claims description 17
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 11
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 10
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 9
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000009477 fluid bed granulation Methods 0.000 claims description 8
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 8
- 229920001983 poloxamer Polymers 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 6
- 108090001061 Insulin Proteins 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 6
- 235000019438 castor oil Nutrition 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 5
- 102000005157 Somatostatin Human genes 0.000 claims description 5
- 108010056088 Somatostatin Proteins 0.000 claims description 5
- 229960000502 poloxamer Drugs 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 229950008882 polysorbate Drugs 0.000 claims description 5
- 229960000553 somatostatin Drugs 0.000 claims description 5
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 4
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 4
- 108090000394 Erythropoietin Proteins 0.000 claims description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 4
- 108010067306 Fibronectins Proteins 0.000 claims description 4
- 102000016359 Fibronectins Human genes 0.000 claims description 4
- 108060003199 Glucagon Proteins 0.000 claims description 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 102000001399 Kallikrein Human genes 0.000 claims description 4
- 108060005987 Kallikrein Proteins 0.000 claims description 4
- 102000016943 Muramidase Human genes 0.000 claims description 4
- 108010014251 Muramidase Proteins 0.000 claims description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 102000013275 Somatomedins Human genes 0.000 claims description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 4
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 4
- 229940047120 colony stimulating factors Drugs 0.000 claims description 4
- 229940116977 epidermal growth factor Drugs 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- 229960004666 glucagon Drugs 0.000 claims description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 239000004026 insulin derivative Substances 0.000 claims description 4
- 229940047124 interferons Drugs 0.000 claims description 4
- 229940047122 interleukins Drugs 0.000 claims description 4
- 239000004325 lysozyme Substances 0.000 claims description 4
- 229960000274 lysozyme Drugs 0.000 claims description 4
- 235000010335 lysozyme Nutrition 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- 229960005356 urokinase Drugs 0.000 claims description 4
- 230000004862 vasculogenesis Effects 0.000 claims description 4
- 102000051325 Glucagon Human genes 0.000 claims 3
- 230000000087 stabilizing effect Effects 0.000 abstract description 21
- 239000007924 injection Substances 0.000 description 46
- 238000002347 injection Methods 0.000 description 46
- 239000000243 solution Substances 0.000 description 37
- 102000004196 processed proteins & peptides Human genes 0.000 description 28
- 230000000694 effects Effects 0.000 description 23
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000000178 monomer Substances 0.000 description 20
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000007921 spray Substances 0.000 description 16
- 229920003116 HPC-SSL Polymers 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 14
- 230000006240 deamidation Effects 0.000 description 13
- 238000011084 recovery Methods 0.000 description 13
- 102000018997 Growth Hormone Human genes 0.000 description 12
- 108010051696 Growth Hormone Proteins 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 11
- 229920001993 poloxamer 188 Polymers 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000008213 purified water Substances 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 238000010254 subcutaneous injection Methods 0.000 description 6
- 239000007929 subcutaneous injection Substances 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 239000013590 bulk material Substances 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 239000007771 core particle Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000012723 sample buffer Substances 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010024825 Loose associations Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000011246 composite particle Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- -1 oral preparations Substances 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101710132632 Protein C4 Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Definitions
- the present invention relates to a physiologically active peptide-containing powder, and in particular to a physiologically active peptide-containing powder in which contamination by denatured peptides has been suppressed by stabilizing the physiologically active peptide and thereby preventing its denaturation from taking place in the process of forming a powder by drying an aqueous liquid containing the physiologically active peptide.
- the present invention further relates to a physiologically active peptide-containing powder suitable for transpulmonary and transnasal administration by inhalation.
- compositions for systemic administration of a drug are under investigation that are intended either for transpulmonary absorption of a pharmacologically active ingredient by inhalation (referred to as an “inhalant composition” in the present specification) or for absorption of such an ingredient through the nasal mucous membrane by intranasal application, i.e. compositions for transnasal administration, as compositions utilizing other, new administration routes than those relied on by conventional pharmaceutical compositions such as injections, oral preparations, suppositories and the like.
- Inhalant compositions and compositions for transnasal administration are not directly injected into the body, but they are applied onto the surface of mucous membranes which are exposed to the air such as membranes of the respiratory tract.
- stabilization of a given active peptide in a production process should be achieved by means of approved pharmaceutical additives which are highly safe and have been used for years. This is because such an additive would allow to expect higher safety with regard to the final pharmaceutical product obtained. It is also required that the absorption and transferal to the blood of an physiologically active peptide is attained in sufficient efficiency.
- the present invention has as its objectives to provide a method to improve stability of a physiologically active peptide in a process of producing a powder by drying an aqueous liquid containing the physiologically active peptide, as well as to provide a physiologically active peptide-containing powder produced by the method.
- the present invention has as its further objectives to provide a physiologically active peptide-containing powder especially suited for absorption of the physiologically active peptide by inhalation, and to provide an inhalant composition.
- the present inventors found that, in a process of preparing a powder containing a physiologically active peptide by drying an aqueous liquid containing the peptide, addition of certain compounds to the aqueous liquid remarkably increases the stability of the physiologically active peptides during the powder preparation.
- the present inventors also found that physiologically active peptides contained in the powder thus prepared are efficiently absorbed into the blood when the powder is transpulmonarily administered. The present invention was made on the basis of these findings.
- the present invention provides a method for stabilization of a physiologically active peptide in a process of preparing a powder containing the physiologically active peptide by drying an aqueous liquid containing the physiologically active peptide, wherein the method comprises adding to the aqueous liquid at least one compound selected from the group consisting of a nonionic surfactant, a water-soluble, nonionic, organic binder, hydrogenated lecithin, and mannitol.
- a nonionic surfactant a water-soluble, nonionic, organic binder, hydrogenated lecithin and mannitol serve as stabilizers in preparing a powder containing a physiologically active peptide from an aqueous liquid containing it.
- these compounds employed suppress denaturation such as dimer formation in the process of forming a powder from an aqueous liquid containing the peptide, thereby enabling to prepare a physiologically active peptide-containing powder which is substantially free of denatured peptides.
- the present invention further provides a method for stabilization of a physiologically active peptide in a process of preparing a powder containing the physiologically active peptide by drying an aqueous liquid containing the physiologically active peptide, wherein the method comprises adding to the aqueous liquid mannitol and at least one compound selected from the group consisting of a nonionic surfactant, a water-soluble, nonionic, organic binder, and hydrogenated lecithin.
- This method enables, in addition to the above-mentioned benefit, to prepare a powder effecting especially efficient transpulmonary absorption of a physiologically active peptide.
- the concentration range where they exhibit a potent stabilizing effect is 0.01-0.5 % by weight for a nonionic surfactant and 0.01-1 % by weight for a water-soluble, nonionic, organic binder.
- mannitol it exhibits a potent stabilizing effect when added in an amount of 1-50 parts by weight per one part by weight of a physiologically active peptide.
- the nonionic surfactant is selected from the group consisting of polysorbate, polyoxyethylenehydrogenated castor oil, and a poloxamer (polyoxyethylene polyoxypropylene block copolymer: Pluronic).
- the water-soluble, nonionic, organic binder is more preferably selected from the group consisting of polyvinylpyrrolidone, a water-soluble, nonionic, cellulose derivative and polyvinylalcohol.
- the water-soluble, nonionic, cellulose derivative is more preferably selected from the group consisting of hydroxypropylcellulose, hydroxyethylcellulose, and hydroxypropylmethylcellulose.
- a still more preferable concentration range for a nonionic surfactant is 0.05-0.3 % by weight, where a particularly potent stabilization effect is obtained.
- a concentration range still more preferable than the above is 0.02-0.5 % by weight, where a particularly potent stabilization effect is obtained.
- hydrogenated lecithin its stabilizing effect is particularly remarkable even at a concentration as low as 0.01% by weight. While its effect peaks at concentrations of 0.5-1 % by weight, the effect remains still remarkable outside this range, and even at 2% by weight.
- the decline in its stabilizing effect is only limited even when its concentration goes up beyond the peak concentration.
- An upper limit concentration therefore, is not clear over which hydrogenated lecithin would substantially lose its stabilizing effect.
- concentration may be chosen as desired considering ease of handling in production of the pharmaceutical composition as there is no reason for using an unnecessarily large amount of hydrogenated lecithin insofar as it exhibits a sufficient effect as an additive.
- the concentration of hydrogenated lecithin is preferably in the range of about 0.005-4% by weight, and more preferably in the range of 0.01-2% by weight.
- the weight proportion of a physiologically active peptide to mannitol is more preferably 1:1 to 1:40, further more preferably 1:1 to 1:30, still more preferably 1:1 to 1:20, and most preferably 1:1 to 1:10.
- any of the above stabilizers may be used alone, or two or more of them may be used in combination. When used in combination, they exhibit a still more remarkable stabilizing effect than when one of them is used alone, thus allowing to almost completely prevent the formation of denatured peptide such as a dimer.
- the present invention is characterized in that its uses, in drying an aqueous liquid containing a physiologically active peptide, a certain group of compounds that were found to stabilize active peptides.
- the compounds can be used in a wide variety of specific methods for drying.
- example of methods for drying aqueous liquids include, but are not limited to, spray drying, lyophilization and spray-freeze drying, and, furthermore, a variety of methods which include a process of drying a solution by spraying it, such as drying performed in fluid-bed granulation, in a variety of coating method such as fluid-bed coating which allow to coat the surface of core particles, as well as drying performed in a granulation process in fluid-bed granulation involving coating of, or attachment of materials to, the surface of core particles.
- Inhaled particles are more easily carried on the air flow deep into the respiratory system when their average size is 1-10 ⁇ m, and more preferably 2-5 ⁇ m.
- the particles of the physiologically active peptide-containing powder obtained in a stable form by one of the above methods are easily carried deep into the respiratory system by inhalation, allowing efficient and relatively long-lasting transferal of the physiologically active peptide into the circulating blood.
- the present invention further provides one of the above method in which the average size of the particles making up the powder is 1-10 ⁇ m, and more preferably 2-5 ⁇ m.
- Examples of active peptides stabilized according to the present invention include calcitonins, insulins, growth hormones, erythropoietin, glucagon, somatostatin, somatostatin derivatives, interferons ( ⁇ , ⁇ or ⁇ ), interleukins (I, II, III, IV, V VI or VII), superoxide dismutase, urokinase, proteases, tumor necrosis factors, colony-stimulating factors, kallikrein, lysozyme, fibronectin, as well as a variety of factors regulating growth or differentiation of cells such as insulin-like growth factors, epidermal growth factor, fibroblast growth factors, platelet-derived growth factor, nerve growth factor, hepatocyte growth factor, vasculogenesis factors, and anti-vasculogenesis factors.
- active peptides share a common chemical structure that they consist of two or more amino acids linked by peptide bonds
- the present invention is also applicable to a wide variety of other active peptides than those enumerated above. Moreover, it does not matter whether those peptides have been obtained by extraction from natural sauces or produced by application of genetic recombination technology, for such difference will not influence the basic physicochemical characters of the peptides.
- human growth hormone and human insulin are particularly preferred peptides in the present invention, for they are such peptides that patients have had to continue administering themselves by subcutaneous injection for a long period of time
- the present invention provides a method for preparation of a powder containing a physiologically active peptide.
- the method for preparation comprises forming a powder by drying an aqueous liquid containing a physiologically active peptide and a nonionic surfactant, a water-soluble, nonionic, organic binder, hydrogenated lecithin, and/or mannitol.
- a physiologically active peptide-containing powder is prepared which is substantially free of denatured peptides.
- the present invention further provides a method for preparation of a powder containing a physiologically active peptide, wherein the method comprises forming a powder by drying an aqueous liquid containing the physiologically active peptide, mannitol, and at least one compound selected from the group consisting of a nonionic surfactant, a water-soluble, nonionic, organic binder, and hydrogenated lecithin.
- This method for preparation in addition to the above-mentioned benefit, provides a powder that effects especially efficient transpulmonary absorption of a physiologically active peptide.
- the nonionic surfactant is more preferably selected from the group consisting of polysorbate, polyoxyethylenehydrogenated castor oil, and a poloxamer (polyoxyethylene polyoxypropylene block copolymer: Pluronic).
- the water-soluble, nonionic, organic binder is more preferably selected from the group consisting of polyvinylpyrrolidone, a water-soluble, nonionic, cellulose derivative and polyvinylalcohol.
- the water-soluble, nonionic, cellulose derivative is more preferably selected from the group consisting of hydroxypropylcellulose, hydroxyethylcellulose, and hydroxypropylmethyl-cellulose.
- preferable ranges of the amount of the enumerated stabilizers when employed are the same as those mentioned for them in the method for stabilization of physiologically active peptides above. Therefore, a still more preferable concentration range for a nonionic surfactant is 0.05-0.3% by weight, and, for a water-soluble, nonionic, organic binder, a still more preferable concentration range is 0.02-0.5% by weight.
- a nonionic surfactant is 0.05-0.3% by weight
- a still more preferable concentration range is 0.02-0.5% by weight.
- hydrogenated lecithin an upper limit concentration is not clear over which hydrogenated lecithin would substantially lose its stabilizing effect.
- the concentration of hydrogenated lecithin is preferably in the range of about 0.005-4% by weight, and more preferably in the range of 0.01-2% by weight.
- the weight proportion of a physiologically active peptide to mannitol is more preferably 1:1 to 1:40, further more preferably 1:1 to 1:30, still more preferably 1:1 to 1:20, and most preferably 1:1 to 1:10.
- example of methods for drying aqueous liquids include, but are not limited to, spray drying, lyophilization and spray-freeze drying, and fluid-bed granulation, as well as a variety of coating method, such as fluid-bed coating, which allow to coat the surface of core particles, and fluid-bed granulation involving coating of, or attachment of materials to, the surface of core particles.
- the average size of the particles making up the powder is preferably 1-10 ⁇ m, and more preferably 2-5 ⁇ m, when considering transpulmonary administration of a physiologically active peptide.
- the present invention further provides a powder containing a physiologically active peptide, wherein the powder is made up of particles comprising a physiologically active peptide and mannitol at a weight proportion of 1:1 to 1:50.
- the particles making up the powder further comprise, per one part by weight of the physiologically active peptide, at least one component selected from the group consisting of a nonionic surfactant in an amount of 0.05-3 parts by weight, a water-soluble, nonionic, organic binder in an amount of 0.05-6 parts by weight, and hydrogenated lecithin.
- a nonionic surfactant in an amount of 0.05-3 parts by weight
- a water-soluble, nonionic, organic binder in an amount of 0.05-6 parts by weight
- hydrogenated lecithin Such a powder effects an efficient absorption of a physiologically active peptide through a mucous membrane deep in the respiratory system.
- the weight proportion of a physiologically active peptide to mannitol in the particles above is more preferably 1:1 to 1:40, further more preferably 1:1 to 1:30, still more preferably 1:1 to 1:20, and most preferably 1:1 to 1:10.
- the amount of a nonionic surfactant is more preferably 0.25-1.8 parts by weight per one part by weight of a physiologically active peptide, in which range efficient absorption of a physiologically active peptide is attained while suppressing the amount of a nonionic surfactant employed.
- the amount of water-soluble, nonionic, organic binder is more preferably 0.1-3 parts by weight per one part by weight of a physiologically active peptide.
- the average size of the particles making up the powder is preferably 1-10 ⁇ m, and more preferably 2-5 ⁇ m.
- Method for preparation of the above powder containing a physiologically active peptide is not limited.
- the powder may be prepared, for example, by spray drying, spray-freeze drying or lyophilization.
- the present invention further provides an inhalant composition containing a physiologically active peptide, wherein the inhalant composition comprises above-mentioned particles containing a physiologically active peptide.
- the inhalant composition may simply be such particles containing a physiologically active peptide, or they may be either clusters consisting of such particles loosely associated with one another or composites consisting of such particles plus larger, inert carrier particles (e.g. lactose) onto the surface of which the former particles are loosely attached.
- Such loose clusters or composites are constructed in an extent of looseness that, at the time of inhaling the composition, they will be disintegrated upon release from an inhalation device by the flow of air and the each fine particle containing a physiologically active peptide will thereby be liberated from the clusters or carriers into a separate particle
- Preparation of such loose clusters or loose and coarse composite particles can be prepared by any of a variety of methods well known to those skilled in the art for bringing particles of the size of one to several ⁇ m making up a powder into a loose association with one another or into a loose association onto larger, inert carrier particles.
- Such loose clusters or loose and coarse composite particles are intended to increase flowability of the composition for improved ease of filling and accuracy of filling amount in a process in which a unit dose of the inhalant compositions is filled into each of predetermined containers like capsules employed in a inhalation device. Therefore, once put in a capsule, it is allowed that the whole or part of particles are liberated to separate particles by external agitation and thus forming a powder within the capsule.
- FIG. 1 is a graph illustrating the effect of nonionic surfactants.
- FIG. 2 is a graph illustrating the effect of water-soluble, nonionic, organic binders.
- FIG. 3 is a graph illustrating the effect of hydrogenated lecithin.
- FIG. 4 shows blood concentration profiles of human growth hormone in rat after transpulmonary administration of a human growth hormone-containing powder and subcutaneous injection of the same amount of the powder.
- an “aqueous liquid containing a physiologically active peptide” includes not only a simple aqueous solution of a physiologically active peptide but also a solution of a physiologically active peptide further containing one or more other components that do not adversely affect the stability of the physiologically active peptide, e.g., buffering agents such as phosphates, pharmaceutically acceptable salts such as sodium chloride, and diluents such as sorbitol.
- buffering agents such as phosphates, pharmaceutically acceptable salts such as sodium chloride, and diluents such as sorbitol.
- the method for stabilization of the present invention stabilizes a physiologically active peptide dissolved in an aqueous liquid in a process of evaporating water from the aqueous liquid, its stabilization effect on a physiologically active peptide is not affected even by drying the physiologically active peptide coated on the surface of larger particles chemically inert to the active peptide, such as lactose and the like.
- Such inert particles serve as cores which carry on their surface a coat of the physiologically active peptide mixed with one or more stabilizing agents
- the powder of the present invention containing a physiologically active peptide is based on the discovery that a very efficient transpulmonary absorption is attained by employing particles comprising a physiologically active peptide and mannitol.
- any method of preparation may be chosen as desired for preparing such powder containing a physiologically active peptide.
- the method of the present invention for preparation of a powder containing a physiologically active peptide is based also on the discovery that mannitol has an effect of remarkably stabilizing a physiologically active peptide in the process of forming a powder by drying an aqueous liquid containing the peptide.
- drying of an aqueous solution containing a physiologically active peptide and mannitol may be performed by any conventional method as desired.
- an example of particularly preferred physiologically active peptides is human growth hormone.
- the term “human growth hormone” means not only 22K hGH extractable from the pituitary of a human, which consists 191 amino acids and has a molecular weight of 22,125, but also 20K hGH, which lacks 15 amino acids corresponding amino acids 32 - 46 . 20K hGH has a growth stimulating effect comparable to 22 K hGH.
- the term “human growth hormone” means not only these natural types of human growth hormones, but also proteins which are produced by application of genetic recombination technology and having a substantially comparable effect to the natural human growth hormones.
- human growth hormone produced by application of genetic recombination technology examples include a N-terminal methionine-type hormone consisting 192 amino acids and variants which have part of their amino acids deleted, substituted, added or inserted and having a comparable activity to the natural types of human growth hormone.
- GH growth hormone
- active peptides the molecule of growth hormone (GH)
- gas-liquid interface As the gas-liquid interface is expanded in a drying process such as spray drying, it is necessary, particularly in the case of GH, to manage to minimize its denaturation induced by this expansion of the interface in the process of forming GH into a powder.
- human growth hormone was chosen as a representative of active peptides.
- the human growth hormone employed in the Examples and Control Examples below was a recombinant human growth hormone (in which N-terminal methionine had been selectively deleted enzymaticaly) which had the same amino acid sequence as the natural human growth hormone consisting of 191 amino acids (22K hGH).
- the recombinant human growth hormone is identified as “Growject Injection 4 IU”, it indicates that a pharmaceutical product (Growject Injection 4 IU: JCR pharmaceuticals, Co., Ltd.) was employed there.
- the composition of Growject Injection 4 IU is as follows. Where the recombinant human growth hormone is specifically noted as a “bulk material”, it indicates the pure recombinant human growth hormone (produced by BTG), which is free of any additives.
- r-hGH Injection (Growject Injection 4 IU): (Formula) (Formula) r-hGH 4 IU (1.7 mg) Disodium hydrogenphosphate 2.2 mg Sodium dihydrogenphosphate 0.35 mg Sodium chloride 1.0 mg D-mannitol 20.0 mg
- Tests will be described below which were performed by spray drying as a representative model of drying processes of an aqueous liquid containing a physiologically active peptide.
- the apparatus employed for spray drying was Spray Dryer SD-1000 (EYELA).
- recovery rate of the physiologically active peptide monomer was employed, for it is considered to be the best indicator of stabilization of the physiologically active peptide. Calculation of recovery rate was done according to the following equation, based on the concentration of the physiologically active peptide in the aqueous liquid before drying (before spray drying) and the content of recovered active peptide in the solution prepared by reconstituting the obtained powder (spray dried product) to the initial volume
- a P area of monomer peak on HPLC for spray dried product
- a I area of monomer peak on HPLC before spray drying.
- Inlet temperature 80° C.
- Atomizing pressure 150 kPa
- Liquid feeder pump flow 2.6 mL/min
- Mobile phase 50 mM sodium dihydrogenphosphate, 50 mM disodium hydrogenphosphate, 0.2 M sodium chloride.
- Inlet temperature 90° C.
- Atomizing pressure 100 kPa
- Fluid feeder pump flow 2.6 mL/min
- aqueous solutions containing Tween 20 at different concentrations were prepared. Fifteen vials of the r-hGH injection (Growject Injection 4IU) were provided for each of the aqueous solutions containing Tween 20 at the different concentrations. The aqueous solutions containing Tween 20 at different concentrations were added to corresponding 15 vials, 1.0 mL each, and the injection was completely dissolved.
- r-hGH solutions containing Tween 20 at different concentrations (15.0 mL: 15 vials for each Tween 20 concentration) were spray-dried to obtain dry powders.
- the conditions for spray drying and HPLC were the same as those in Control Example 1.
- aqueous solutions containing HCO-60 polyoxyethylenehydrogenated castor oil
- concentration: 0.01, 0.05, 0.1, 0.5, 1.0 and 2.0 w/w %) were prepared.
- Fifteen vials of the r-hGH injection (Growject Injection 4IU) were provided for each of the aqueous solutions containing HCO-60 at different concentrations.
- the aqueous solutions containing HCO-60 at different concentrations were added to corresponding 15 vials, 1.0 mL each, and the injection was completely dissolved.
- r-hGH solutions containing HCO-60 at different concentrations (15.0 mL: 15 vials for each HCO-60 concentration) were spray-dried to obtain dry powders.
- the conditions for spray drying and HPLC were the same as those in Control Example 1.
- aqueous solutions containing Pluronic F68 polyoxyethylene(160)polyoxypropylene(30) glycol
- concentration: 0.01, 0.05, 0.1, 0.5, 1.0 and 2.0 w/w %) were prepared.
- Fifteen vials of the r-hGH injection (Growject Injection 4IU) were provided for each of the aqueous solutions containing Pluronic F68 at different concentrations.
- the aqueous solutions containing Pluronic F68 at different concentrations were added to corresponding 15 vials, 1.0 mL each, and the injection was completely dissolved.
- aqueous solutions containing Kollidone 17PF (polyvinylpyrrolidone: BASF) at different concentrations (concentration: 0.01, 0.05, 0.1, 0.5, 1.0 and 2.0 w/w %) were prepared. Fifteen vials of the r-hGH injection (Growject Injection 4IU) were provided for each of the aqueous solutions containing Kollidone 17PF at different concentrations. The aqueous solutions containing Kollidone 17PF at different concentrations were added to corresponding 15 vials, 1.0 mL each, and the injection was completely dissolved.
- Kollidone 17PF polyvinylpyrrolidone: BASF
- r-hGH solutions containing Kollidone 17PF at different concentrations (15.0 mL: 15 vials for each Kollidone 17PF concentration) were spray dried to obtain dry powders.
- the conditions for spray drying and HPLC were the same as those in Control Example 1.
- aqueous solutions containing Kollidone 12PF (polyvinylpyrrolidone: BASF) at different concentrations (concentration: 0.01, 0.05, 0.1, 0.5, 1.0 and 2.0 w/w %) were prepared. Fifteen vials of the r-hGH injection (Growject Injection 4IU) were provided for each of the aqueous solutions containing Kollidone 12PF at different concentrations. The aqueous solutions containing Kollidone 12PF at different concentrations were added to corresponding 15 vials, 1.0 mL each, and the injection was completely dissolved.
- Kollidone 12PF polyvinylpyrrolidone: BASF
- r-hGH solutions containing Kollidone 12PF at different concentrations (15.0 mL: 15 vials for each Kollidone 12PF concentration) were spray-dried to obtain dry powders.
- the conditions for spray drying and HPLC were the same as those in Control Example 1.
- aqueous solutions containing HPC-SSL hydroxypropylcellulose: TOSOH
- concentration: 0.01, 0.05, 0.1, 0.5 and 1.0 w/w %) were prepared.
- Fifteen vials of the r-hGH injection (Growject Injection 4IU) were provided for each of the aqueous solutions containing HPC-SSL at different concentrations.
- the aqueous solutions containing HPC-SSL at different concentrations were added to corresponding 15 vials, 1.0 mL each, and the injection was completely dissolved.
- aqueous solutions containing Lecinol S-10E hydrogenated lecithin: NIKKO CHEMICALS
- concentration: 0.01, 0.05, 0.1, 0.5, 1.0 and 2.0 w/w %) were prepared.
- Fifteen vials of the r-hGH injection (Growject Injection 4IU) were provided for each of the aqueous solutions containing hydrogenated lecithin at different concentrations.
- the aqueous solutions containing hydrogenated lecithin at different concentrations were added to corresponding 15 vials, 1.0 mL each, and the injection was completely dissolved.
- r-hGH solutions containing hydrogenated lecithin at different concentrations (15.0 mL: 15 vials for each hydrogenated lecithin concentration) were spray-dried to obtain dry powders.
- the conditions for spray drying and HPLC were the same as those in Control Example 1.
- Aqueous solutions were prepared which contained HPC-SSL (hydroxypropylcellulose) and a nonionic surfactant in combination as indicated in the following table.
- HPC-SSL hydroxypropylcellulose
- a nonionic surfactant in combination as indicated in the following table.
- FIG. 1 shows the results of HPLC analysis performed in Control Example 1 and Examples 1-3.
- FIG. 2 shows the results of HPLC analysis performed in Control Example 1 and Examples 4-6.
- the water-soluble, nonionic, organic binders markedly increased the recovery rate of the monomer of physiologically active peptide r-hGH in the process of powder preparation from its aqueous solutions.
- Example 4 Kerdone 17PF
- 5 Kerdone 12PF
- Their stabilizing effect was particularly potent up to a concentration of 1 w/w % and peaked at a concentration of 0.1 w/w %.
- Example 6 hydroxypropylcellulose
- stabilizing effect was still more remarkable than where the other binders were employed, showing a r-hGH recovery rate of about 95% at a concentration of 0.1 w/w %, where its effect peaked.
- Example 6 hydroxypropylcellulose was tested only up to the concentration of 1 w/w %. However, it is largely evident that hydroxypropylcellulose would show a stabilizing effect even at 2 w/w %. This is because its effect at 1 w/w % was much higher than the effects of the other organic binders employed in Example 4 and 5 at the same concentration, and the decline in its effect by increasing its concentration beyond the peak is substantially not greater than the decline seen in the graphs for Examples 4 or 5.
- FIG. 3 shows the results of HPLC analysis performed in Control Example 1 and Example 7.
- Example 8 A 0.05 HCO-60 0.05 99.20 ⁇ 1.16
- Example 8 B 0.05 Pluronic F68 0.05 98.42 ⁇ 0.61
- Example 8 C 0.05 Pluronic F68 0.10 97.96 ⁇ 1.34
- Example 8 D 0.10 HCO-60 0.05 104.76 ⁇ 0.68
- Example 8 E 0.10 HCO-60 0.10 104.81 ⁇ 0.17
- GH a recombinant human growth hormone (r-hGH) bulk material was used.
- r-hGH human growth hormone
- stabilizers D-mannitol, HPC-SSL and Pluronic F68 were used.
- r-hGH and additives were weighed and dissolved in 15.0 mL of purified water to prepare spray solutions.
- r-hGH alone was dissolved in 15.0 mL of purified water to prepare a spray solution (Control Formula).
- “% by weight” in parentheses indicates the ratio of the weight of respective solid component to the weight of the solid components as a whole.
- EYELA SD- 1000 Spray Dryer were used as a spray dryer. Dry powders were prepared by spray-drying the above r-hGH solutions. The conditions for spray drying was as follows.
- Inlet temperature 90° C.
- Atomizing pressure 100 kPa
- Fluid feeder pump flow 2.6 mL/min
- Sample amount about 0.02 g/0.5 mL purified water
- Mobile phase 0.1 M sodium dihydrogenphosphate, 0.1 M disodium hydrogenphosphate, 0.2 M sodium chloride.
- Sample amount about 0.02 g/0.5 mL purified water
- Solutions of about 0.04 mg/mL was prepared as samples. To each 10 ⁇ L of the solutions was added 10 ⁇ L of water and 20 ⁇ L of the sample buffer. As a standard sample, a solution of about 1.6 mg r-hGH bulk material/mL was prepared, to 10 ⁇ L of which was added 10 ⁇ L of water and 20 ⁇ L of the sample buffer.
- An electrophoresis buffer for SDS-PAGE was prepared by adding 900 mL of water to 100 mL of the electrophoresis buffer for 10 ⁇ SDS-PAGE.
- (C) A 0.25 M Tris-HCl buffer (pH 6.8) was prepared by adding water to 30.25 g of Tris to make into volume of 800 mL, then adjusting the pH of the solution to 6.8 with 6 N hydrochloric acid, and making into volume of 1000 mL with water (preserved by freezing).
- a sample buffer for SDS-PAGE was prepared by adding water to 25 mL of 0.25 M Tris-HCl buffer (pH 6.8), 2 g of SDS, 5 g of sucrose and 2 mg of bromphenol blue (BPB) to make 50 mL.
- r-hGH, HPC-SSL and D-mannitol were weighed and dissolved in 90 mL of purified water to obtain a spray solution.
- “% by weight” in parentheses indicates the ratio of the weight of respective solid component to the weight of the solid components as a whole.
- the concentration of r-hGH, HPC-SSL and D-mannitol is 0.27% by weight, 0.14% by weight and 2.92% by weight, respectively.
- Spray drying and analyses were performed under the same conditions as in Example 9.
- the areas of the main peak (%) and the peak (%) for deamidation products were as follows. TABLE 4 Area of Monomer Area of Deamidation Products Peak (%) Peak (%) Spray-dried 95.5 4.5 Product Standard 96.6 3.4
- the GH powder was administered to rats for pharmacokinetic evaluation.
- the same amount of the GH powder as transpulmonarily administered was dissolved in water and subcutaneously administered to rats to compare its pharmacokinetics with that of transpulmonarily administered GH.
- the rats of the transpulmonary administration group were anesthetized with urethane.
- Two mg/kg rat body weight of the r-hGH powder was placed in a transpulmonary administration device for rats (PennCentury).
- the powder was discharged into the lungs of the rats through the device's delivery tube inserted in the trachea by thrusting out 3 mL of air from a syringe connected to the device.
- the rats of the subcutaneous administration group were also fasted for a full day and night and then subcutaneously injected with the r-hGH powder suspended in purified water in an amount equivalent to 2 mg/kg rat body weight.
- Blood sampling was performed just before the administration of r-hGH and then 0, 15, 30, 60, 120, 240, 480 and 1440 minutes thereafter. Blood was sampled from the cervical vein of restrained rats. Blood sampling volume was 300 ⁇ L at one time. Following each blood sampling, the same amount (300 ⁇ L) of physiological saline was injected into the cervical vein. Blood samples were let stand for one hour at room temperature and then overnight at 4° C., and centrifuged (15,000 rpm, 10 minutes, 4° C.) to separate the sera.
- An anti-hGH rabbit polyclonal antibody raised by a conventional method was diluted and adjusted to the absorbance OD280 of 0.02 with a 0.05 M Tris buffer. The solution was placed, 100 ⁇ L each, in the wells of 96-well plates and incubated for two hours at 37° C. The plates were washed five times with a 0.01 M phosphate buffer (washing buffer). The wells of the plates were filled with a block solution (Block Ace: Dainippon Pharmaceutical Co., Ltd.) and let stand overnight at 4° C.
- HRP horseradish peroxidase
- Table 5 and FIG. 4 show r-hGH concentrations in the blood after transpulmonary administration of the r-hGH powder or subcutaneous injection of the r-hGH suspension. TABLE 5 Time after Blood r-hGH Concentration (ng/ml) Administration Transpulmonary Subcutaneous (min) Administration Injection 0 22.6 41.5 15 584.4 423.1 30 451.4 446.1 60 315.1 491.8 120 254.9 423.9 240 101.6 347.9 480 61.5 175.5 1440 34.7 51.3
- the blood concentration of r-hGH following transpulmonary administration was lower than that following its subcutaneous injection, except for a period immediately after pulmonary administration.
- the above results show that r-hGH absorption after transpulmonary administration of the composition was very high.
- the blood r-hGH concentration after the transpulmonary administration of the very composition was far higher than either of the blood r-hGH concentration after the transpulmonary administration or subcutaneous administration of the same amount of r-hGH suspension carried out in Control Example 3 below.
- r-hGH and lactose were weighed and dissolved in 120 mL of purified water to obtain a spray solution.
- concentration of r-hGH and lactose in the spray solution is 0.20 w/w % and 2.30 w/w %, respectively.
- Lactose (monohydrate) 2.760 g (92.0% by weight)
- Inlet temperature 120° C.
- Fluid feeder pump flow 2.6 mL/min
- r-hGH was transpulmonarily administered or subcutaneously injected to male 9-week-old Wistar rats, six animals per group, following the same dose and procedures as indicated in “Pharmacokinetic Evaluation of GH Powder after Transpulmonary Administration to Rats”, and the pharmacokinetics for r-hGH was determined. The results are shown in the table below. TABLE 7 Time after Blood r-hGH Concentration (ng/ml) Administration Transpulmonary Subcutaneous (min) Administration Injection 0 5 6 15 147 46 30 129 52 60 85 62 120 70 75 240 58 71 480 48 21 1440 37 5
- Natural human growth hormone, 22K hGH, is composed of 191 amino acids, with two S-S bonds within the molecule, whereas human insulin is composed of 51 amino acids and has two S-S bonds within the molecule. It is reasonably expected that transpulmonary absorption demonstrated above with the powders containing human growth hormone will occur also with human insulin, considering that the far smaller molecule of human insulin compared with human growth hormone will render the former more suitable for absorption through mucous membranes and that it shares a structural similarity with human growth hormone in light that they have two S-S bonds within their molecule. Likewise, successful transpulmonary absorption is expected to take place also with calcitonin (32 amino acids) and somatostatin (28 amino acids), which are roughly of half the size of human insulin, by forming them into the powder of the present invention.
- the present invention enables to remarkably stabilize a physiologically active peptide in forming a powder by drying an aqueous solution containing the physiologically active peptide, thereby minimizing loss of the peptide in the process of powder formation.
- the present invention also enables to produce a powder stably retaining a physiologically active peptide, without evoking unnecessary concerns on the safety of such a product due to employed additives.
- the present invention alto enables to provide physiologically active peptide-containing powder in which content of dimers or other denatured peptide is minimized, thereby making it easy to produce such types of pharmaceutical compositions that are adapted to be applied to mucous membranes in a powder form in order to introduce a drug into the circulating blood, e.g. pharmaceutical compositions for transnasal or transpulmonary administration.
- the present invention further enables to provide inhalant compositions which allow efficient transferal of growth hormone or insulin into the blood by transpulmonary administration.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/994,773 US7235253B2 (en) | 2000-03-21 | 2001-11-28 | Powder containing physiologically active peptide |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000078775 | 2000-03-21 | ||
JP2000-78775 | 2000-03-21 | ||
JP2000310693 | 2000-10-11 | ||
JP2000-310693 | 2000-10-11 | ||
JP2001015904A JP4711520B2 (ja) | 2000-03-21 | 2001-01-24 | 生理活性ペプチド含有粉末 |
JP2001-15904 | 2001-01-24 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/994,773 Division US7235253B2 (en) | 2000-03-21 | 2001-11-28 | Powder containing physiologically active peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020009789A1 true US20020009789A1 (en) | 2002-01-24 |
Family
ID=27342741
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/810,483 Abandoned US20020009789A1 (en) | 2000-03-21 | 2001-03-19 | Powder containing physiologically active peptide |
US09/994,773 Expired - Fee Related US7235253B2 (en) | 2000-03-21 | 2001-11-28 | Powder containing physiologically active peptide |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/994,773 Expired - Fee Related US7235253B2 (en) | 2000-03-21 | 2001-11-28 | Powder containing physiologically active peptide |
Country Status (3)
Country | Link |
---|---|
US (2) | US20020009789A1 (fr) |
EP (1) | EP1136068B1 (fr) |
JP (1) | JP4711520B2 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030022828A1 (en) * | 1998-10-16 | 2003-01-30 | Rama Akella | Povidone-containing carriers for polypeptide growth factors |
US20050002909A1 (en) * | 2000-04-07 | 2005-01-06 | Centerpulse Biologics Inc | Methods and compositions for treating intervertebral disc degeneration |
US20060204448A1 (en) * | 2003-03-04 | 2006-09-14 | Takahiro Matsuyama | Powdery preparation for nasal administration |
US20060216325A1 (en) * | 1997-08-14 | 2006-09-28 | Atkinson Brent L | Composition and device for in vivo cartilagerepair |
US20070212365A1 (en) * | 2003-10-30 | 2007-09-13 | Kazusa Dna Research Institute Foundation | Novel Plexin Polypeptide, Dna Encoding the Same and Use Thereof |
US20100041611A1 (en) * | 2002-06-26 | 2010-02-18 | Kevin Thorne | Rapid Isolation of Osteoinductive Protein Mixtures From Mammalian Bone Tissue |
US7772182B2 (en) | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
US20120213846A1 (en) * | 2008-08-15 | 2012-08-23 | Forest Laboratories Holdings Limited | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7022683B1 (en) | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
US7785625B2 (en) * | 2000-01-14 | 2010-08-31 | Lg Life Sciences, Limited | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
US20030064105A1 (en) * | 2000-08-25 | 2003-04-03 | Myung-Jin Kim | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
AU2001291721A1 (en) * | 2000-08-25 | 2002-03-04 | Merck Patent G.M.B.H | Powdered mannitol and mannitol-containing compositions |
US7494669B2 (en) * | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
US6777000B2 (en) * | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
KR20040093155A (ko) * | 2002-03-18 | 2004-11-04 | 야마노우치세이야쿠 가부시키가이샤 | 흡입용 분말 의약조성물 및 이의 제조방법 |
US7008644B2 (en) | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
WO2004016247A1 (fr) * | 2002-08-14 | 2004-02-26 | E.I. Du Pont De Nemours And Company | Procede d'enrobage d'une particule pharmaceutique |
ITBA20020032A1 (it) * | 2002-09-24 | 2004-03-25 | Bio D Soc | Metodo per stabilizzare le proteine per la conservazione ad alte temperature. |
GB0228689D0 (en) * | 2002-12-09 | 2003-01-15 | Elan Drug Delivery Ltd | Compositions |
CA2578250C (fr) | 2004-07-26 | 2013-03-05 | Merz Pharma Gmbh & Co. Kgaa | Composition therapeutique avec neurotoxine botulique |
DE102006009534A1 (de) * | 2006-02-28 | 2007-08-30 | Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH | Verfahren zum Aufbewahren des humanen Wachstumshormons Somatotropin und Verfahren zum quantitativen Nachweis des humanen Wachstumshormons Somatotropin |
WO2009023803A2 (fr) * | 2007-08-15 | 2009-02-19 | Abbott Respiratory Llc | Formulation à libération modulée pour la distribution d'un ou de plusieurs médicaments |
US20100266569A1 (en) * | 2007-11-15 | 2010-10-21 | Mark Zylka | Prostatic acid phosphatase for the treatment of pain |
EP2106788A1 (fr) * | 2008-04-04 | 2009-10-07 | Ipsen Pharma | Formulations liquides et lyophilisées |
WO2010017965A2 (fr) * | 2008-08-11 | 2010-02-18 | Merck Serono S.A. | Microcapsules de lipides solides contenant hgh |
JP6992262B2 (ja) * | 2016-03-31 | 2022-02-15 | 東ソー株式会社 | 変性抗体測定試薬の製造方法 |
JP6901801B2 (ja) * | 2017-06-14 | 2021-07-14 | バイオソリューション カンパニー・リミテッドBio Solution Co Ltd | 物質pを含むしわの改善または抗炎症化粧料組成物 |
US11110063B2 (en) | 2017-08-25 | 2021-09-07 | MAIA Pharmaceuticals, Inc. | Storage stable sincalide formulations |
CN107802828B (zh) * | 2017-11-29 | 2018-09-11 | 广东天普生化医药股份有限公司 | 一种激肽释放酶注射液 |
EP3970696A4 (fr) * | 2019-05-16 | 2023-03-01 | Shin Nippon Biomedical Laboratories, Ltd. | Préparation de poudre pour administration transnasale et son procédé de production |
WO2024080308A1 (fr) * | 2022-10-12 | 2024-04-18 | 中外製薬株式会社 | Composition contenant un peptide, un tensioactif et un polymère |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4976968A (en) * | 1989-02-24 | 1990-12-11 | Clinical Technologies Associates, Inc. | Anhydrous delivery systems for pharmacological agents |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
US5334162A (en) * | 1993-03-15 | 1994-08-02 | Eli Lilly And Company | Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same |
US5607915A (en) * | 1992-09-29 | 1997-03-04 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
US5654278A (en) * | 1994-10-13 | 1997-08-05 | Novo Nordisk A/S | Composition and method comprising growth hormone and leucine |
US5705482A (en) * | 1995-01-13 | 1998-01-06 | Novo Nordisk A/S | Pharmaceutical formulation |
US5839443A (en) * | 1996-05-16 | 1998-11-24 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation |
US5898030A (en) * | 1994-06-17 | 1999-04-27 | Applied Research Systems Ars Holding N.V | hGH containing pharmaceutical compositions |
US5955448A (en) * | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
US5997848A (en) * | 1994-03-07 | 1999-12-07 | Inhale Therapeutic Systems | Methods and compositions for pulmonary delivery of insulin |
US6117434A (en) * | 1995-03-23 | 2000-09-12 | The Nisshin Oil Mills Ltd. | Humectant composition, base containing the same, and cosmetic material or external preparation containing said humectant composition |
US6455053B1 (en) * | 1997-10-09 | 2002-09-24 | Ssp Co., Ltd. | Quickly soluble solid preparations |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4615885A (en) * | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
JPS61194034A (ja) * | 1985-02-25 | 1986-08-28 | Teijin Ltd | 経鼻投与用粉末状組成物 |
CA2020654A1 (fr) * | 1989-07-07 | 1991-01-08 | Yohko Akiyama | Compose fgf stabilise et sa production |
JPH05963A (ja) * | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
KR100277622B1 (ko) * | 1992-06-12 | 2001-01-15 | 이타가키 히로시 | 흡입용 초미립자 분말 및 그의 제조방법 |
JP2962578B2 (ja) * | 1992-06-12 | 1999-10-12 | 帝人株式会社 | 気道内投与用容器入り製剤 |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
JP3622015B2 (ja) * | 1992-10-08 | 2005-02-23 | 敏一 中村 | 肺傷害治療剤 |
JPH06271478A (ja) * | 1993-03-23 | 1994-09-27 | Otsuka Pharmaceut Co Ltd | ドライアイ治療剤 |
JPH0779364A (ja) | 1993-09-06 | 1995-03-20 | Ikegami Tsushinki Co Ltd | スクロール装置 |
ES2125474T3 (es) * | 1993-09-06 | 1999-03-01 | Ishihara Sangyo Kaisha | Derivados de piridazinona o sus sales, procedimentos para su produccion y agentes anti-shock que los contienen. |
JP3323305B2 (ja) | 1993-12-24 | 2002-09-09 | 旭化成株式会社 | エルカトニン安定化剤 |
JP3294695B2 (ja) | 1993-12-24 | 2002-06-24 | 旭化成株式会社 | エルカトニン水溶液剤の振とう安定化剤 |
JP3323306B2 (ja) | 1993-12-24 | 2002-09-09 | 旭化成株式会社 | エルカトニン水溶液剤の安定化剤 |
IL115592A (en) | 1994-10-13 | 2000-07-26 | Novo Nordisk As | Stabilized pharmaceutical formulation comprising a growth hormone and leucine |
SE9403526D0 (sv) * | 1994-10-14 | 1994-10-14 | Astra Ab | New Peptides |
EP0807433A4 (fr) * | 1994-12-27 | 2005-12-28 | Akzo Nobel Nv | Preparation a liberation prolongee |
US6258341B1 (en) * | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
JPH10265404A (ja) * | 1996-02-02 | 1998-10-06 | Mitsui Chem Inc | ヒト成長ホルモンを含有する医薬製剤 |
US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
US6017549A (en) * | 1997-09-30 | 2000-01-25 | E-L Management Corp. | Non-irritating cosmetic and pharmaceutical compositions |
ZA989744B (en) * | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
US6655379B2 (en) * | 1998-03-16 | 2003-12-02 | Nektar Therapeutics | Aerosolized active agent delivery |
US6284282B1 (en) * | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
-
2001
- 2001-01-24 JP JP2001015904A patent/JP4711520B2/ja not_active Expired - Fee Related
- 2001-03-19 EP EP01106382A patent/EP1136068B1/fr not_active Expired - Lifetime
- 2001-03-19 US US09/810,483 patent/US20020009789A1/en not_active Abandoned
- 2001-11-28 US US09/994,773 patent/US7235253B2/en not_active Expired - Fee Related
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
US4976968A (en) * | 1989-02-24 | 1990-12-11 | Clinical Technologies Associates, Inc. | Anhydrous delivery systems for pharmacological agents |
US5607915A (en) * | 1992-09-29 | 1997-03-04 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
US5334162A (en) * | 1993-03-15 | 1994-08-02 | Eli Lilly And Company | Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same |
US5997848A (en) * | 1994-03-07 | 1999-12-07 | Inhale Therapeutic Systems | Methods and compositions for pulmonary delivery of insulin |
US5898030A (en) * | 1994-06-17 | 1999-04-27 | Applied Research Systems Ars Holding N.V | hGH containing pharmaceutical compositions |
US5955448A (en) * | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
US5654278A (en) * | 1994-10-13 | 1997-08-05 | Novo Nordisk A/S | Composition and method comprising growth hormone and leucine |
US5705482A (en) * | 1995-01-13 | 1998-01-06 | Novo Nordisk A/S | Pharmaceutical formulation |
US6117434A (en) * | 1995-03-23 | 2000-09-12 | The Nisshin Oil Mills Ltd. | Humectant composition, base containing the same, and cosmetic material or external preparation containing said humectant composition |
US5839443A (en) * | 1996-05-16 | 1998-11-24 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation |
US6455053B1 (en) * | 1997-10-09 | 2002-09-24 | Ssp Co., Ltd. | Quickly soluble solid preparations |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090297605A1 (en) * | 1997-08-14 | 2009-12-03 | Atkinson Brent L | Composition And Device For In Vivo Cartilage Repair |
US20060216325A1 (en) * | 1997-08-14 | 2006-09-28 | Atkinson Brent L | Composition and device for in vivo cartilagerepair |
USRE41286E1 (en) | 1997-08-14 | 2010-04-27 | Zimmer Orthobiologics, Inc. | Compositions for regeneration and repair of cartilage lesions |
US6992066B2 (en) * | 1998-10-16 | 2006-01-31 | Zimmer Orthobiologics, Inc. | Povidone-containing carriers for polypeptide growth factors |
US20030022828A1 (en) * | 1998-10-16 | 2003-01-30 | Rama Akella | Povidone-containing carriers for polypeptide growth factors |
US7341999B2 (en) | 1998-10-16 | 2008-03-11 | Zimmer Orthobiologics, Inc. | Povidone-containing carriers for polypeptide growth factors |
US20080113916A1 (en) * | 1998-10-16 | 2008-05-15 | Zimmer Orthobiologies, Inc. | Povidone-Containing Carriers for Polypeptide Growth Factors |
US20050002909A1 (en) * | 2000-04-07 | 2005-01-06 | Centerpulse Biologics Inc | Methods and compositions for treating intervertebral disc degeneration |
WO2003060076A2 (fr) * | 2001-12-21 | 2003-07-24 | Centerpulse Biologics, Inc. | Excipients contenant de la povidone pour facteurs de croissance polypeptidiques |
WO2003060076A3 (fr) * | 2001-12-21 | 2004-03-04 | Ct Pulse Biolog Inc | Excipients contenant de la povidone pour facteurs de croissance polypeptidiques |
US8829166B2 (en) | 2002-06-26 | 2014-09-09 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
US20100041611A1 (en) * | 2002-06-26 | 2010-02-18 | Kevin Thorne | Rapid Isolation of Osteoinductive Protein Mixtures From Mammalian Bone Tissue |
US20060204448A1 (en) * | 2003-03-04 | 2006-09-14 | Takahiro Matsuyama | Powdery preparation for nasal administration |
US7591999B2 (en) | 2003-03-04 | 2009-09-22 | Mitsubishi Tanabe Pharma Corporation | Powdery preparation for nasal administration |
US20090215170A1 (en) * | 2003-10-30 | 2009-08-27 | Hisashi Koga | Plexin family-like polypeptide, DNA encoding the same and uses thereof |
US7482322B2 (en) | 2003-10-30 | 2009-01-27 | Kazusa Dna Research Institute Foundation | Plexin family-like polypeptide, and uses thereof |
US7816132B2 (en) | 2003-10-30 | 2010-10-19 | Kazusa Dna Research Institute Foundation | DNA encoding plexin polypeptides and kits thereof |
US20070212365A1 (en) * | 2003-10-30 | 2007-09-13 | Kazusa Dna Research Institute Foundation | Novel Plexin Polypeptide, Dna Encoding the Same and Use Thereof |
US7772182B2 (en) | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
US20120213846A1 (en) * | 2008-08-15 | 2012-08-23 | Forest Laboratories Holdings Limited | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration |
Also Published As
Publication number | Publication date |
---|---|
JP4711520B2 (ja) | 2011-06-29 |
JP2002187852A (ja) | 2002-07-05 |
EP1136068B1 (fr) | 2012-11-21 |
EP1136068A2 (fr) | 2001-09-26 |
EP1136068A3 (fr) | 2003-04-02 |
US20020058624A1 (en) | 2002-05-16 |
US7235253B2 (en) | 2007-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7235253B2 (en) | Powder containing physiologically active peptide | |
EP0805822B1 (fr) | Erythropoietine sechee par pulverisation | |
AU627174B2 (en) | Human growth hormone formulation | |
FI116195B (fi) | Menetelmät ja koostumukset insuliinin antamiseksi keuhkojen kautta | |
JP5628026B2 (ja) | 安定した非水性薬学的組成物 | |
US20150031609A1 (en) | Methods and compositions for delivering peptides | |
JPH0430926B2 (fr) | ||
JP2004535401A (ja) | 化学的に改変されたインスリンの肺投与 | |
US7262168B2 (en) | Compositions providing for increased IGF-I solubility | |
JP2001525372A (ja) | 安定化テリパラチド溶液剤 | |
JP2010529956A5 (fr) | ||
WO2009053106A1 (fr) | Formulations de l'hormone parathyroïde et utilisations de celles-ci | |
EP1641486B1 (fr) | Solutions aqueuses stables d'erythropoietine humaine ne contenant pas d'albumine serique | |
US6331520B1 (en) | Pharmaceutical compositions of peptides having low solubility in physiological medium | |
WO1994015584A1 (fr) | Solution contenant l'igf-1 | |
US20030113273A1 (en) | Methods and compositions for pulmonary delivery of insulin | |
JP4931282B2 (ja) | 生理活性ペプチド含有粉末 | |
AU778208C (en) | GRF-containing lyophilized pharmaceutical compositions | |
EP1028748B1 (fr) | Compositions pour obtenir une solubilite amelioree du facteur igf-i | |
WO1997007816A1 (fr) | Solution contenant l'igf-i |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: JCR PHARMACEUTICAL CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HANYU, YOSHINOBU;OKADA, MARIKO;SHINDO, CHIHIRO;AND OTHERS;REEL/FRAME:012015/0286;SIGNING DATES FROM 20010613 TO 20010618 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |